Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18673424 | Combination Therapy for Treatment of Liver Disease | Non-Final OA | Novo Nordisk A/S |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | Non-Final OA | Novo Nordisk A/S |
| 18254166 | INJECTABLE BIODEGRADABLE POLYMERIC COMPLEX FOR GLUCOSE-RESPONSIVE INSULIN DELIVERY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17920698 | INHIBITION OF SARS-COV-2 VIRAL ENTRY THROUGH ORAL ADMINISTRATION OF LACTOFERRIN AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 19341996 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Final Rejection | ELI LILLY AND COMPANY |
| 19338984 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Non-Final OA | ELI LILLY AND COMPANY |
| 18031833 | AAV8 AFFINITY AGENTS | Non-Final OA | Repligen Corporation |
| 17914207 | FIBRILLATION RESISTANT CALCITONIN PEPTIDES AND USES THEREOF | Final Rejection | Purdue Research Foundation |
| 17504500 | GLP-1R AGONIST REDUCES RETINAL INFLAMMATION AND NEURON DEATH SECONDARY TO OCULAR HYPERTENSION | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17909689 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | Final Rejection | Sanofi |
| 18250977 | INHIBITORS OF ANGIOGENIC FACTORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18283112 | REGULATORY T CELL-INDUCING PEPTIDE AND COMPOSITION INCLUDING SAME FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | Non-Final OA | MEDIMMUNE LIMITED |
| 18617015 | STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME | Final Rejection | Xeris Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy